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Abstract The study explored the awareness of the Haute
Autorite´ de Sante´ (High Health Authority, HAS) guidelines
for migraine management in children among a random
sample of 100 general practitioners (GPs) dichotomised in
an urban and a rural group. A questionnaire conducted
by phone included questions on knowledge of pediatric
migraine acute treatment and preventive therapy, referral to
a child neurologist as well as GPs awareness of HAS rec-
ommendations in general. Although 45% of GPs argued
they were prescribing ibuprofen as first-line abortive drug,
only 3% were aware of the recommended dose. Only 48%
of GPs were agreeing to initiate preventive therapy. Fifty
percent of GPs stated that they knew HAS guidelines but
only 24% stated that they had read them. The only sig-
nificant difference between urban and rural GPs concerned
the initiation of preventive therapy. Continuing educational
programmes on the implementation of pediatric migraine
guidelines is strongly needed.
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Introduction
The estimated prevalence of migraine in the adolescent
population ranges from 8% to 28% [1–3]. Migraine in
adolescents also has been associated with disability as
evidenced by missed school days [1, 4], and a negative
impact on quality of life [5].
Despite this high prevalence, however, clinicians may
not readily recognize childhood migraine [6] and treatment
appears even less satisfactory. There are many drug and
non-drug therapeutic approaches for both acute and pre-
ventive treatment. The French Health Agency (High Health
Authority, Haute Autorite´ de Sante´, HAS) regularly issues
clinical guidelines intended to general practitioners (GPs)
dealing with the diagnosis and/or the therapeutic manage-
ment of various medical conditions. Clinical guidelines for
the therapeutic management of migraines in adults and
children were published in 2002 and sent to every GP in
France [see Appendix (Supplementary material)] [7]. In a
previous study designed to assess the impact of these
measures and the management of children with headaches,
we analyzed the pre-referral management by GPs of
children referred to our Consulting Center in the
Neuropediatric Department of Lille University Hospital
Center, in northern France and compared it with the rec-
ommended therapeutic management of migraines in
children, such as it was issued by the HAS [8]. Our study
showed that, even when the GP did diagnose migraine,
adequate and logical disease management did not follow
and was not in accordance with HAS guidelines in the
majority of cases.
The objective of the present study was to investigate
GPs’ knowledge of therapeutic management of migraines
in children, and in particular, their awareness of HAS
guidelines for migraine management in children.
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Methods
From 1 August 2007 to 31 March 2008, a survey was
conducted on a random sample of 100 GPs in the northern
area of France. All the GPs sampled were contacted by
phone and invited to participate to the study by answering a
questionnaire. They were dichotomised in two groups (50
GPs each) whether they were working in an urban or rural
area. If the invited GP declined to participate to the study,
the next GP on the list was contacted. The interviewed GPs
were informed that the study concerned pediatric migraine
but they were unaware of the precise study subject, in order
to obtain the more spontaneous answers as possible.
The questionnaire included questions focusing on GPs’
behavior in terms of the management of pediatric migraine
in their daily practice and their knowledge of HAS rec-
ommendations. It was composed of single and multiple
choice items, as well as closed questions. Questions 1–5
concerned acute treatment, questions 6–7 preventive
therapy. Questions 8–10 had a larger scope and were
dealing with GPs awareness of HAS recommendations.
Quantitative variables were compared using the v2 test. A
probability level of P \ 0.05 was considered significant.
Table 1 shows the 10 questions asked in questionnaire.
Correlations between questions 1–4 and, respectively,
questions 9 and 10 were calculated using Pearson v2 test.
Results
One hundred and forty-three GPs were contacted by phone
during the study period. Forty-three GPs declined to par-
ticipate to the study, arguing either they were too busy
(n = 31, 22%), or they had no interest for the issue of
pediatric migraine (n = 12, 8%). The mean age of the
sample of GPs was 42.3 years (range 35–68 years). The
majority of theses GPs were men (95%). As expected 100
GPs were included in the study, divided in an urban
[n = 50, mean age 41.7 years (range 35–66 years), men
92%] and a rural group [n = 50, mean age 42.9 years
(range 36–68 years), men 98%]. Table 2 shows the
respondents’ behavior about pediatric migraine patient
management and awareness of HAS recommendations.
Abortive treatment (Questions 1–5)
Acute medications
Forty-five GPs argued they were prescribing ibuprofen as
first-line abortive drug, whereas 44 GPs argued they were
prescribing ibuprofen as second-line intention migraine
abortive drug. The second most frequently prescribed
medication was paracetamol, which was prescribed as
Table 1 Questionnaire
Question 1b
What is your first intention acute medication for a migraine attack










What is your second intention acute medication for a migraine attack









When you prescribe ibuprofen for a migraine attack, which dose of
ibuprofen do you prescribe?
1. 7.5–10 mg/kg/dose
2. Dose recommended for body weight
3. Other
Question 4b
When you prescribe ibuprofen for a migraine attack, which number
of ibuprofen doses do you prescribe for a single migraine attack?
1. 1–2 doses
2. [ 2 doses
Question 5a
If you do not prescribe ibuprofen as first intention acute medication
for a migraine attack, why?
1. Ibuprofen is not the reference medication
2. Too long onset of action
3. Adverse effects/toxicity




Which criteria do you take into account to start preventive treatment?
1. Frequency of migraine attacks
2. Intensity of migraine attacks
3. Functional disability
4. Failure and/or poor tolerance of abortive drugs
5. Other
Question 7b
Which type of preventive treatment do you start in first intention?
1. Pharmacological treatment
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first-line drug by 44 GPs and as second-line drug by 24
GPs. Aspirin was prescribed as first-line drug by 10 GPs
and as second-line drug by 12 GPs. Eleven GPs asserted
prescribing sumatriptan nasal spray as second-line drug.
Target dose
Among the 99 GPs prescribing ibuprofen (as first or second-
line acute treatment), 96 targeted no particular dose. They
contented themselves with either using oral solution dosage
recommended for body weight or tablets. In this case, they
prescribed 100 mg per dose for those with a body weight of
20–39 kg, and 200 mg per dose for those with a body weight
of 40 kg or more. Three GPs targeted a dose of 10 mg/kg and
1 GP was prescribing ibuprofen at a dose of 5 mg/kg.
Administration schedule
The first-line medication was prescribed with a maximum
of one to two doses for a single migraine attack by 44 GPs.
Reasons for refusing to prescribe ibuprofen as first-line
acute treatment
Among the 55 GPs who did not prescribe ibuprofen as first-
line acute treatment, 26 (47%) did so by fear of the
potential adverse events, 15 (27%) had in mind that
ibuprofen was not the reference medication of pediatric
migraine attack, 8 (15%) were unaccustomed to prescribe
ibuprofen in pediatric migraine, 5 (9%) were finding ibu-
profen ineffective in pediatric migraine, and 1 (2%) were
finding that ibuprofen onset of action was too long.
Preventive treatment (Questions 6 and 7)
Reasons for starting preventive treatment
Preventive therapy for migraine was considered by 76 GPs
when migraine attacks were frequent, by 55 GPs when the
headache were becoming disabling and so were impeding
routine activities, by 41 GPs when acute treatment was
ineffective or when there were intolerable adverse effects
from GPs when the treatment, and by 27 GPs because of
severity of the migraine attacks.
Type of preventive treatment
Forty-eight GPs were agreeing to initiate preventive therapy.
Forty GPs were prescribing pharmacological treatment (83%
of those agreeing to start preventive therapy) and 8 GPs were
prescribing non-pharmacological treatment (17% of those
agreeing to start preventive therapy).
Referring the patient to a child neurologist (Question 8)
Referral to a child neurologist was considered by 17 GPs
when first-line acute treatment was ineffective, by 53 GPs
when second-line acute treatment was ineffective, by 56
GPs when migraine attacks were frequent and/or disabling,
and by 6 GPs as a matter of course. Three GPs said that
they never referred pediatric patients to a child neurologist
because waiting period to obtain an appointment consul-
tation was too long.
Awareness of HAS guidelines for the therapeutic
management of pediatric migraine (Questions 9 and 10)
Knowledge of the HAS guidelines for the therapeutic
management of pediatric migraine
Fifty GPs stated that they knew HAS guidelines for the
therapeutic management of pediatric migraine. The per-
centage was higher for rural (60%) than for urban GPs
(48%), but the difference was not significant (P = 0.31).
Reading HAS guidelines for the therapeutic management
of pediatric migraine
Twenty-four percent of GPs stated that they had read HAS





When do you refer a pediatric migraine patient to a specialist?
1. Failure of abortive drugs of first intention migraine attacks
2. Failure of abortive drugs of second intention
3. Frequent and/or disabling migraine attacks
4. To start preventive treatment
5. As a matter of course
6. Other
Question 9b
Do you think being aware of the HAS guidelines for the therapeutic




Did you read last HAS guidelines for the therapeutic management of
acute treatment of pediatric migraine?
1. Yes
2. No
a For each question, tick appropriate numbers. Several answers pos-
sible. Code all that apply
b For each question, tick appropriate number. Only one possible
answer
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Table 2 Awareness of respondents about management of pediatric migraine
Total Urban Rural OR [CI]
Question 1. Medication of first intention
1. Aspirin 10 14 6 1.2 [0.4–3.8]
2. Diclofenac 0 0 0 –
3. Ibuprofen 45 36 54 0.5 [0.2–1.1]
4. Niflumic acid 1 2 0 0.3 [0.1–8.2]
5. Opioids 0 0 0 –
6. Paracetamol 44 48 40 1.3 [0.6–3.1]
7. Sumatriptan 0 0 0 –
8. Other 0 0 0 –
Question 2. Medication of second intention
1. Ibuprofen 44 46 42 1.2 [0.5–2.5]
2. Ergotamine 2 4 0 3.1 [0.1–77]
3. Opioids 0 0 0 –
4. Paracetamol 24 18 30 0.5 [0.2–1.3]
5. Sumatriptan 16 12 10 0.9 [0.3–2.9]
6. Other triptan 1 2 0 3.01 [0.1–77]
7. Aspirin 12 14 10 1.5 [0.6–3.9]
Question 3. Dose of ibuprofen
1. 7.5–10 mg/kg/dose 3 2 4 0.5 [0.08–2.7]
2. Dose recommended for body weight 96 96 96 1 [0.13–7.4]
3. Other 1 2 0 5.2 [0.2–111]
Question 4. Number of ibuprofen doses
1. 1–2 doses 44 50 38 1.6 [0.7–3.6]
2. [2 doses 56 50 62 0.6 [0.3–1.4]
Question 5. Reasons of ibuprofen non prescription
1. Not the reference medication 17 20 14 1.8 [0.6–5.4]
2. Too long onset of action 2 4 0 5.2 [0.2–111]
3. Adverse effects/toxicity 26 26 26 1
4. Not indicated/ineffective 6 6 6 1
5. No answer 45 36 54 –
6. Free answer 8 16 0 –
Question 6. Criteria to start preventive treatment
1. Frequency of migraine attacks 76 64 88 0.3 [0.1–0.7]*
2. Intensity of migraine attacks 27 28 26 1.1 [0.5–2.7]
3. Functional disability 55 52 58 0.8 [0.4–1.8]
4. Failure/poor tolerance of abortive drugs 41 36 46 0.7 [0.3–1.5]
5. Other 6 12 0 –
Question 7. Type of first intention preventive treatment
1. Pharmacological treatment 40 22 58 0.3 [0.1–0.5]*
2. Non-pharmacological treatment 8 10 6 1.8 [0.4–7.7]
3. None 52 68 36 2.3 [1, 1–5]*
Question 8. Referral to a specialist
1. Failure of first intention abortive drug 17 14 20 7.4 [0.4–147]
2. Failure of second intention abortive drug 53 58 48 1.4 [0.7–3.3]
3. Frequent and/or disabling attacks 56 58 54 1.6 [0.7–3.5]
4. Start preventive treatment 52 58 46 2.1 [0.3–12]
5. As a matter of course 6 8 4 0.8 [0.3–2.4]
6. Other 3 6 0 –
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migraine. The percentage was identical both for rural and
urban GPs. Figure analyzes knowledge of reference treat-
ment of pediatric migraine by the GPs according to
knowledge of the HAS guidelines for the therapeutic
management of pediatric migraine. Figure also shows GPs
prescription of ibuprofen according to their knowledge of
the treatment of reference. Fifty-four GPs stated that they
knew the treatment recommended for pediatric migraine.
Among these GPs, 18 (33%) stated that they had read HAS
guidelines for the therapeutic management of pediatric
migraine (Fig. 1). Among the 54 GPs stating being aware
of the reference treatment, 33 (61%) were prescribing
ibuprofen as first-line acute drug for pediatric migraine
(Fig. 1). Forty-six GPs stated that they did not know
the reference treatment among which 5 (11%) had read
HAS guidelines (Fig. 1). Among these 46 GPs, 12 (26%)
were nevertheless prescribing ibuprofen as first-line acute
(Fig. 1). Seventy-seven GPs stated that they never had read
2002 HAS guidelines. There was no significant correlation
between the fact of answering questions 1–4 correctly and
knowledge of the HAS guidelines (P = 0.243) or reading
of the HAS guidelines (P = 0.059). Conversely, the cor-
relation between stating to know HAS guidelines and
stating having read them was significant (P = 0.008).
Discussion
Acute medications
Few well-designed trials have evaluated the acute phar-
macologic management of migraine in children [9, 10]. In
1997, the study by Ha¨ma¨la¨inen et al. [11] was the first
randomized, double-blind, placebo-controlled trial
dedicated to abortive treatment of pediatric migraine. It
compared acetaminophen (15 mg/kg) and ibuprofen
(10 mg/kg) in a single dose three-way crossover study that
showed that both drugs were well-tolerated and effective in
relieving migraine attacks. Another study showed that a
lower ibuprofen dosage (7.5 mg/kg) was more effective
than placebo in reducing headache severity at 2 h [12].



































Fig. 1 HAS guidelines and
ibuprofen prescription
according to knowledge of
reference treatment. HAS Haute
Autorite´ de Sante´, High Health
Authority
Table 2 continued
Total Urban Rural OR [CI]
Question 9. Knowledge of HAS guidelines for pediatric migraine
1. Yes 54 48 60 0.6 [0.3–1.3]
2. No 46 52 40 1.6 [0.7–3.5]
Question 10. Reading of HAS guidelines for pediatric migraine
1. Yes 24 24 24 1 [0.4–2.5]
2. No 76 76 76 1 [0.4–2.5]
OR odds ratio, CI confidence interval
* P \ 0.05
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ibuprofen and placebo. They found that ibuprofen 200–
400 mg was more effective than placebo in meeting pain
relief after 2 h [13].
The HAS guidelines for the treatment of migraine in
adults and children were issued in October 2002 (see
Appendix) [7]. These guidelines are currently under
revision. New guidelines are expected to be issued in
2009. They were sent to each GP working in France. The
HAS recommended ibuprofen as the mainstay drug for
acute migraine attacks in children aged 6 months or older.
It also recommended switching to ergot derivatives from
the age of 10 onward and to sumatriptan nasal spray in
children and adolescents 12 or older in case of inefficacy
of ibuprofen. Although the HAS did not advocate the use
of paracetamol in its guidelines for the treatment of
migraine in adults and children, paracetamol was the drug
of choice favoured by GPs. Moreover, when a little less
than half of the GPs would prescribe ibuprofen as first
intention drug for migraine attack, only 3% of the GPs
interviewed knew the correct dosage. This figure is in line
with the data of a previous survey from our hospital,
where we analyzed previous headache treatment by GPs
in 151 consecutive children referred for migraines to our
out-patient neuropaediatric department [8]. In this study,
ibuprofen was prescribed to only 30.3% of the children
and only 15.2% of the children were both prescribed an
appropriate dose of ibuprofen and told to take it early in
the course of the attack. Another concern raised by this
previous study was the fact that GPs seemed reluctant to
assess the efficacy of their prescribed drug as abortive
medication. In case of inefficacy, they often advised
children and adolescents to take paracetamol more fre-
quently, and in last resort, every day [8]. This is in
accordance with the present finding that 54% of GPs did
not limit number of doses taken during the same attack.
Medication overuse
Excessive symptomatic medication may conduct to
medication overuse (MO) which has been proposed as a
risk factor for migraine transformation. The pediatric
prevalence of MO is much variable within published
hospital series (0–82.5%) [14–23]. In a general popula-
tion study, MO was seen in 0.3% of 12–14 years
Taiwanese adolescents [24] and in 0.5% of 13–18 years
Norwegians adolescents, with a higher rate for girls
(0.8%) than for boys (0.2%) [25]. Whereas all drugs
used in the acute treatment of migraine bear the risk of
MO, ‘‘simple’’ analgesics seem wrongly considered as
‘‘harmless’’ by GPs [26]. This might explain the high
rate of MO encountered in our daily practice. In our
already mentioned previous survey, we found that only
9.1% of patients had been warned about drug abuse [8].
Another previous study, dedicated to chronic daily
headache (CDH) conducted in our department, showed
that analgesic abuse was present in 52.9% of them [27].
At the time when this paper was published, this MO rate
ranked third within published series of CDH in children
and adolescents. The two published series which had a
greater percentage of analgesic abuse were those of
Esposito et al. [20] and Vasconcellos et al. [22], where
MO rate amounted to respectively, 82.5 and 65%.
Reasons for ibuprofen under prescription
One of the reasons that may impede ibuprofen as first
intention choice abortive drug is the fear about adverse
events. Ibuprofen is the non-steroidal anti-inflammatory
drug most prescribed for the treatment of fever and
moderate pain in childhood. At a dosage of 4–10 mg/kg,
it is as effective a pediatric analgesic as acetaminophen,
7–15 mg/kg, whereas at a dosage of 5–10 mg/kg,
especially a 10 mg/kg dosage, it is a more efficacious
pediatric antipyretic than acetaminophen, 10–15 mg/kg
[28]. However, concern was raised as lot of studies (case
reports, cohort studies, case–control studies and one
multicenter double-blind randomized control trial) had
reported ibuprofen adverse effects at therapeutics doses.
They documented an increased risk of invasive group
A streptococcal infection after chickenpox and of acute
renal failure in case of hypovolemia after a treatment by
ibuprofen. In the largest randomized-controlled clinical
trial ever conducted to assess the safety of antipyretic
use in 2-year-old [29], the data indicated that inci-
dence rates for serious adverse clinical events requiring
hospitalization among febrile children treated with acet-
aminophen or ibuprofen were low and did not vary
significantly with choice of antipyretic. The meta-analy-
sis by Perrott et al. [28] also concluded that the data
available so far did not provide any evidence that both
drugs differed in safety from each other or from placebo.
Nevertheless, as a precaution, ibuprofen was not rec-
ommended for the treatment of fever or moderate pain
during chickenpox or during a disease with a risk of
dehydration, until other pharmacoepidemiological studies
more accurately quantified the risk of adverse events of
ibuprofen in children. As a consequence, fearing of GPs
appears excessive as most of pediatric migraine attacks
may not occur during chickenpox or during a disease
with a risk of dehydration.
Preventive therapy
There is currently no consensus about when to initiate
preventive measures, but daily preventive therapy is war-
ranted in about 20–30% of young migraineurs [30]. Most
172 J Headache Pain (2009) 10:167–175
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authors consider three to four migraines per month as the
threshold for considering the preventive treatment in
pediatric patients. Besides headache frequency, the deci-
sion to initiate preventive therapy must also take into
account the disability caused by the headache disorder.
Headache diaries are extremely valuable for an accurate
determination of frequency, severity, and disability and
provide a basis for decisions about preventive therapy [31].
Uncommon migraine conditions such as basilar or hemi-
plegic migraines [32], patients who are unable to tolerate,
overuse, or have contraindications for acute therapies
should also be considered for prophylactic therapy [32].
Patient preference in addition to financial issues may
warrant therapy as well [32].
We can only speculate why 52% of GPs deliberately
refused to initiate preventive therapy. In a community
sample of adolescents, nearly one third of adolescent mi-
graineurs met criteria for preventive therapy, whereas only
19% received it [33]. The Ce´leste study was a 6-month
prospective multicenter study conducted in France which
included 486 children and adolescents with primary head-
ache, whose aim was to assess clinical features and
therapeutic management throughout France [34]. In the
Ce´leste study, around 10% of children were prescribed a
preventive therapy by GPs (submitted). Moreover GPs
largely favoured ‘‘old’’ preventive medications. Ergot
alkaloids and serotonin antagonists were the two most
often prescribed drugs. Newer preventive drugs, such as
antiepileptic medications were rarely prescribed by GPs.
The information that preventive therapy was advisable in
some instances, irrespective of whether that particular child
should or should not have preventive therapy initiated, was
provided to 22.3% of the children diagnosed with migraine
by their GPs.
Behavioral headache treatments include relaxation
training, biofeedback training, cognitive-behavioral ther-
apy, or combinations of these treatments. The availability
of these therapies is limited in France. This may explain
that GPs favoured pharmacologic versus non-pharmaco-
logic preventive treatments. In the Ce´leste study, few
patients benefited from non-pharmacologic treatments at
referral. Nevertheless, following the re-evaluation by a
neuropediatrician, the increase in preventive therapy
concerned much more non-pharmacologic than pharma-
cologic measures. Whereas there was a nearly twofold
increase in prophylactic treatment prescription, there was
a fivefold and a 23-fold increase for both psychotherapy
and relaxation training, respectively. Biofeedback pre-
scription increased from 0 to 8 patients between pre-
referral and referral. These findings may also indicate
that besides limited availability, there may also be a lack
of knowledge of the possibility of these therapeutic
options by GPs.
Referral
Studies investigating the utility of referring patients with
headache to a specialist are important for several rea-
sons, including planning for optimal care for headache
patients to a reasonable cost for the society. The referral
decision is a complex process involving aspects related
to patient’s factors, clinical factors, consultant factors
and time available for the consultation [35]. In an
adult study, variables such as pain intensity, number of
migraine symptoms, attack duration and disability were
associated with increased frequency of consultation [36].
Such studies on reasons for specialist referral regarding
headache are relatively sparse in children, despite the
fact that headache represents one of the most common
complaints for pediatric patients seeking health services
in general practice as well as in secondary care [37, 38].
In the already cited survey from our hospital, reasons of
referral of migraine pediatric patients to our out-patient
neuropaediatric department were failure to control the
headaches in 37.8% of cases and as a matter of course in
37.1% [8].
Awareness and reading of HAS guidelines
Clinical practice guidelines are systematically developed
statements to assist practitioner and patient decisions
about appropriate health care for specific clinical cir-
cumstances. Their successful implementation should
improve quality of care by decreasing inappropriate var-
iation and expediting the application of effective advances
to every day practice [39, 40]. Despite wide promulga-
tion, guidelines have had limited effect on changing
physician behavior [41–43]. In general, little is known
about the process and factors responsible for how physi-
cians change their practice methods when they become
aware of a guideline [44, 45]. Physician adherence to
guidelines may be hindered by a variety of barriers, which
include lack of awareness, lack of familiarity, and lack of
agreement with guidelines, lack of self-efficacy, lack of
outcome expectancy, the inertia of previous practice, and
external barriers. Any French physician should be aware
of HAS guidelines as they were distributed to every GP in
France. In the study by Bianco et al. [46] dedicated to
headache patient management by general practitioners in
Italy, less than half (46.7%) of the GPs modified the
treatment when new scientific evidence indicated that its
use for a patient was less efficacious that the new one. It
seems to us that the two main factors responsible are lack
of familiarity and inertia of previous practice. We could
not find a correlation between knowledge of the HAS
guidelines, as reflected by the GPs answering correctly to
questions 1–4, and their statement of either knowledge or
J Headache Pain (2009) 10:167–175 173
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reading of the HAS guidelines, which may stem from the
small sample size.
Differences between urban and rural GPs
There were few differences between the urban and the rural
GPs. The only significant difference concerned the initia-
tion of preventive therapy. Rural GPs were more likely to
initiate preventive therapy than urban GPs. Maybe this may
stem from the fact that urban GPs have greater involvement
in chronic disease management. In contrast, the distance
which patient live from a specialist consultation did not
hinder referral to a specialist. Compliance with HAS
guidelines was similarly not different between urban and
rural GPs.
Study limitations
Our study has several limitations. The 70% response rate
may mean that the respondents were not fully representa-
tive of the population of GPs. The majority of GPs of our
sample were men (95%), whereas the general gender dis-
tribution in North of France is around 80%. We have no
explanation for this point. However, our analyses suggest
that our respondents did not differ substantially on all other
demographic and practice characteristics from the overall
population of North of France GPs. Another potential
methodological limitation in the way of collecting infor-
mation on awareness of HAS guidelines and behavior in
management of pediatric migraine patients may have
implications regarding the interpretation of the results,
since such data were obtained from a self-administered
questionnaire by the GPs and may therefore be subject to
recall bias. The possibility of a false answer by the GPs
should also be considered.
Conclusion
Given the prevalence of migraine in the pediatric popula-
tion, children with migraines suffer if forced to apply to
specialist centers for proper treatment. GPs must become
more involved in the management of pediatric migraine.
Thus GPs should rely on and apply the clinical guidelines
for management of migraines in children. Practising
guidelines takes time to incorporate best external evidence
with clinical expertise, GPs need to learn how to use tools
that allow them to find, critically appraise and apply the
evidence to their pediatric patients. Interventions to
improve adherence should also endeavor to identify and
overcome barriers that hinder adherence to the imple-
mentation of recommendations by GPs.
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